Table 1 Study enrollment and results

CohortNBKM120N pt BKM120 interrupted/reduced (AE)*PDPR (Cycle completed)SD (Cycle completed)NE
1A DL1380 mg daily2 (confusion, ALT)101 (22)1 (a)
1A DL26100 mg daily3 (ALT, rash)22 (13,3 (a))2 (9, 7)0
1A DL2b2100 mg intermittent0002 (6, 6)0
1B10100 mg intermittent6 (AST, ALT, rash Hyperglycemia)02 (15+, 12)5 (16+, 9+, 9, 6, 6)3 (a, a, b)
C10100 mg daily5 (rash, ALT, diarrhea, tremor)23 (9+, 8+, 4+)3 (3+, 3+, 3+)#2 (1+, 2+)
Total (N)31 1657136

*All occurred in C2+ except the diarrhea, CBR: 63%, NE: Not evaluable, a: off due to AE, b: withdrew consent, # NE for CBR